약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 4.

Table. 4. Spending trends of RSA listed high-priced medicines by drug characteristics (unit: 1,000,000 KRW)
Category 2014 2016 2018 2020 2021 (%) CAGR
Total RSA drugs1) 31,977 133,142 484,547 802,529 1,038,892 (100.0%) 64.4%
Cost per patient (million KRW/patient)
Low (10~50) 31,977 97,521 428,089 681,307 910,974 (87.7%) 61.4%
Middle (50~100) 13,914 24,414 25,248 (2.4%) 22.0%
High (100~300) 5,516 809 86,755 (8.4%)
Extra high (300+) 30,104 42,543 95,999 15,915 (1.5%) -12.0%
Supplier type
International 31,977 97,521 438,581 743,335 966,570 (93.0%) 62.7%
Domestic 35,620 45,966 59,194 72,322 (7.0%) 15.2%
ATC category
A16A 6,023 12,883 18,350 15,915 (1.5%) 21.5%
B01A 3,423 7,583 6,597 (0.6%) 24.4%
B02B 710 3,502 (0.3%)
D11A 48,286 (4.6%)
L01B 732 718 487 134 72 (0.0%) -28.2%
L01E . 25,633 162,761 288,832 345,419 (33.2%) 68.2%
L01F 17,776 27,718 191,733 295,539 421,814 (40.6%) 57.2%
L01X . . 27,298 55,579 68,643 (6.6%) 36.0%
L02B . 16,308 21,511 22,331 24,031 (2.3%) 8.1%
L04A 13,469 56,743 64,451 69,568 62,960 (6.1%) 24.6%
M09A 42,452 38,193 (3.7%)
N07X 1,450 1,848 (0.2%)
V10X 1,614 (0.2%)
Economic Evaluation Exemption (EEE)
EEE 10,082 61,981 134,424 161,018 (15.5%) 74.0%
Non-EEE 31,977 123,059 422,566 668,105 877,874 (84.5%) 60.5%

1) RSA drugs include RSA-finished drugs as well.

Yakhak Hoeji 2023;67:388-97 https://doi.org/10.17480/psk.2023.67.6.388
© 2023 Yakhak Hoeji